Test IDs patients who may benefit from olaparib, 2/17

February 2017—Myriad Genetics announced that its BRACAnalysis CDx test accurately identified patients who may benefit from treatment with olaparib. The test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.

SOLO2 compared maintenance olaparib against placebo in patients with platinum-sensitive relapsed ovarian cancer. In this study, patients were tested for germline BRCA mutations as determined by the BRACAnalysis CDx test. The primary endpoint for SOLO2 was progression-free survival. The aim was to determine whether patients carrying gBRAC mutations treated with olaparib as a second-line maintenance therapy experienced longer progression-free survival, compared with those patients receiving placebo. The results showed that the olaparib-treated patients achieved the primary endpoint of prolonged PFS.

Myriad Genetics, 800-469-7423